Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.51 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current... 
Via Benzinga
Topics Government
Why BioNTech Stock Bumped Higher Today
Investors were cheered by two pieces of good news concerning the biotech's most famous product. 
Via The Motley Fool
Curious about the most active S&P500 stocks in today's session?
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest... 
Via Chartmill
Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up
Via Stocktwits
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
MTSR Shares Jump After Pfizer Merger Agreement
Metsera stock skyrocketed 62% as Pfizer struck a $4.9 billion acquisition agreement focused on obesity therapies. 
Via Talk Markets
Why Pfizer Stock Just Popped
Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Gold Gains Over 1%; Quantum Computing Shares Plunge
 
Via Benzinga
IBD 50's Tempus AI Hits Record High On Yet Another FDA Clearance
The company is focusing on RNA sequencing as a means of assisting with drug development. 
Via Investor's Business Daily
Topics Artificial Intelligence Intellectual Property
Pfizer Claws Deeper Into The Obesity Space With $4.9 Billion Metsera Deal
The deal follows two high-profile failures for Pfizer, which is trying to broaden its small pipeline in weight loss. 
Via Investor's Business Daily
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal
Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to its pipeline. 
Via Benzinga
3 Dirt-Cheap Stocks to Buy Right Now
These stocks share several common denominators, including attractive valuations. 
Via The Motley Fool
Topics Intellectual Property
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market
Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs. 
Via Benzinga
Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details
The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday. 
Via Stocktwits
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
From Pfizer Inc.
Via Business Wire
Trump Administration To Unveil Tylenol-Autism Review, Tout This Drug As Potential Treatment: Report
Trump administration to announce concerns about Tylenol use in pregnancy and potential treatment for autism, in line with President's priority. 
Via Benzinga
Topics Government
3 Bargain Stocks for Investors on a Budget
If every one of your dollars counts, make sure you're getting the biggest possible bang for your buck. 
Via The Motley Fool
Topics Economy
Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon
There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
A high yield is only one part of the story when it comes to picking dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These stocks are bargains now. But they probably won't be by the end of this decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids
Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines. 
Via Investor's Business Daily
Stay informed about the most active stocks in the S&P500 index on Friday's session.
Looking for the most active stocks in the S&P500 index on Friday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market. 
Via Chartmill
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle
The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like... 
Via MarketMinute
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery... 
Via MarketMinute
Topics Animal Testing Artificial Intelligence Intellectual Property
3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Everything is going great for the stock market right now. But a plot twist could be on the way. 
Via The Motley Fool
Topics Economy
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.